A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

NCT ID: NCT01516541

Last Updated: 2016-11-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

2220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in patients with stable coronary heart disease (CHD), with CHD risk equivalents or at elevated risk for cardiovascular disease. Eligible patients will be randomized to receive either dalcetrapib 600 mg orally daily or placebo orally daily, on a background of contemporary, guidelines-based medical care. Anticipated time on study treatment is 4 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dalcetrapib

Dalcetrapib 600 mg orally daily on a background of contemporary, guidelines-based medical care.

Group Type EXPERIMENTAL

Background care

Intervention Type OTHER

Guidelines-based medical care

dalcetrapib

Intervention Type DRUG

600 mg orally daily

Placebo

Placebo orally daily, on a background of contemporary, guidelines-based medical care.

Group Type PLACEBO_COMPARATOR

Background care

Intervention Type OTHER

Guidelines-based medical care

Placebo

Intervention Type DRUG

Matching dalcetrapib placebo orally daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Background care

Guidelines-based medical care

Intervention Type OTHER

Placebo

Matching dalcetrapib placebo orally daily

Intervention Type DRUG

dalcetrapib

600 mg orally daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients, \>/= 45 years of age
* Established cardiovascular disease A stable coronary disease B cerebrovascular disease C peripheral artery disease
* Without established coronary disease D pharmacologically treated type 2 diabetes mellitus and one or more risk factor(s) for cardiovascular disease E 3 or more risk factors for cardiovascular disease
* Receiving evidence-based medical and dietary management of dyslipidemia

Exclusion Criteria

* Occurrence of myocardial infarction, hospitalization for unstable angina, stroke or revascularization (coronary, carotid or peripheral) within three months prior to randomization
* Uncontrolled hypertension
* Uncontrolled diabetes
* Concomitant treatment with any other drug raising HDL-C
* Previous treatment with compounds targeting cholesteryl ester transfer protein (CETP)
Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Birmingham, Alabama, United States

Site Status

Huntsville, Alabama, United States

Site Status

Anaheim, California, United States

Site Status

Fullerton, California, United States

Site Status

San Diego, California, United States

Site Status

Santa Ana, California, United States

Site Status

Santa Rosa, California, United States

Site Status

Torrance, California, United States

Site Status

Torrance, California, United States

Site Status

Colorado Springs, Colorado, United States

Site Status

Denver, Colorado, United States

Site Status

Lonetree, Colorado, United States

Site Status

Bridgeport, Connecticut, United States

Site Status

Hartford, Connecticut, United States

Site Status

Boynton Beach, Florida, United States

Site Status

Daytona Beach, Florida, United States

Site Status

Daytona Beach, Florida, United States

Site Status

Fort Myers, Florida, United States

Site Status

Jacksonville, Florida, United States

Site Status

Panama City, Florida, United States

Site Status

Plantation, Florida, United States

Site Status

Port Charlotte, Florida, United States

Site Status

Tallahassee, Florida, United States

Site Status

Tampa, Florida, United States

Site Status

West Palm Beach, Florida, United States

Site Status

Covington, Georgia, United States

Site Status

Cumming, Georgia, United States

Site Status

Decatur, Georgia, United States

Site Status

Aurora, Illinois, United States

Site Status

Rock Island, Illinois, United States

Site Status

Winfield, Illinois, United States

Site Status

Elkhart, Indiana, United States

Site Status

Hammond, Indiana, United States

Site Status

Indianapolis, Indiana, United States

Site Status

Indianapolis, Indiana, United States

Site Status

Muncie, Indiana, United States

Site Status

South Bend, Indiana, United States

Site Status

Overland Park, Kansas, United States

Site Status

Louisville, Kentucky, United States

Site Status

Alexandria, Louisiana, United States

Site Status

Bangor, Maine, United States

Site Status

Beltsville, Maryland, United States

Site Status

Salisbury, Maryland, United States

Site Status

Boston, Massachusetts, United States

Site Status

Haverhill, Massachusetts, United States

Site Status

Hyannis, Massachusetts, United States

Site Status

North Dartmouth, Massachusetts, United States

Site Status

Jackson, Michigan, United States

Site Status

Kalamazoo, Michigan, United States

Site Status

Marquette, Michigan, United States

Site Status

Midland, Michigan, United States

Site Status

Rochester Hills, Michigan, United States

Site Status

Saginaw, Michigan, United States

Site Status

Ypsilanti, Michigan, United States

Site Status

Rochester, Minnesota, United States

Site Status

Saint Cloud, Minnesota, United States

Site Status

Chesterfield, Missouri, United States

Site Status

Columbia, Missouri, United States

Site Status

Kansas City, Missouri, United States

Site Status

Kalispell, Montana, United States

Site Status

Nashua, New Hampshire, United States

Site Status

Camden, New Jersey, United States

Site Status

Haddon Heights, New Jersey, United States

Site Status

Mine Hill, New Jersey, United States

Site Status

Wayne, New Jersey, United States

Site Status

Westwood, New Jersey, United States

Site Status

Albany, New York, United States

Site Status

Albany, New York, United States

Site Status

Buffalo, New York, United States

Site Status

Cortlandt Manor, New York, United States

Site Status

Poughkeepsi, New York, United States

Site Status

Saratoga Springs, New York, United States

Site Status

Smithtown, New York, United States

Site Status

Syracuse, New York, United States

Site Status

The Bronx, New York, United States

Site Status

Troy, New York, United States

Site Status

Asheville, North Carolina, United States

Site Status

Durham, North Carolina, United States

Site Status

Elizabeth City, North Carolina, United States

Site Status

Hickory, North Carolina, United States

Site Status

Morehead City, North Carolina, United States

Site Status

Rocky Mount, North Carolina, United States

Site Status

Statesville, North Carolina, United States

Site Status

Wilmington, North Carolina, United States

Site Status

Fargo, North Dakota, United States

Site Status

Cincinnati, Ohio, United States

Site Status

Cleveland, Ohio, United States

Site Status

Mansfield, Ohio, United States

Site Status

Mentor, Ohio, United States

Site Status

Thornville, Ohio, United States

Site Status

Toledo, Ohio, United States

Site Status

Zanesville, Ohio, United States

Site Status

Allentowm, Pennsylvania, United States

Site Status

Altoona, Pennsylvania, United States

Site Status

Camp Hill, Pennsylvania, United States

Site Status

Doylestown, Pennsylvania, United States

Site Status

Erie, Pennsylvania, United States

Site Status

Erie, Pennsylvania, United States

Site Status

Langhorne, Pennsylvania, United States

Site Status

Lansdale, Pennsylvania, United States

Site Status

North Wales, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Pottstown, Pennsylvania, United States

Site Status

Tipton, Pennsylvania, United States

Site Status

West Chester, Pennsylvania, United States

Site Status

Anderson, South Carolina, United States

Site Status

Greer, South Carolina, United States

Site Status

Rapid City, South Dakota, United States

Site Status

Johnson City, Tennessee, United States

Site Status

Dallas, Texas, United States

Site Status

Humble, Texas, United States

Site Status

Odessa, Texas, United States

Site Status

Tyler, Texas, United States

Site Status

Provo, Utah, United States

Site Status

Charlottesville, Virginia, United States

Site Status

Danville, Virginia, United States

Site Status

Lynchburg, Virginia, United States

Site Status

Manassas, Virginia, United States

Site Status

Richmond, Virginia, United States

Site Status

Winchester, Virginia, United States

Site Status

Milton, Queensland, Australia

Site Status

Geelong, Victoria, Australia

Site Status

Joondalup, Western Australia, Australia

Site Status

Coquitlam, British Columbia, Canada

Site Status

Kelowna, British Columbia, Canada

Site Status

Vancouver, British Columbia, Canada

Site Status

Moncton, New Brunswick, Canada

Site Status

Ajax, Ontario, Canada

Site Status

Barrie, Ontario, Canada

Site Status

Burlington, Ontario, Canada

Site Status

Cambridge, Ontario, Canada

Site Status

Greater Sudbury, Ontario, Canada

Site Status

Greater Sudbury, Ontario, Canada

Site Status

London, Ontario, Canada

Site Status

Oakville, Ontario, Canada

Site Status

Oshawa, Ontario, Canada

Site Status

Oshawa, Ontario, Canada

Site Status

Thunder Bay, Ontario, Canada

Site Status

Toronto, Ontario, Canada

Site Status

Granby, Quebec, Canada

Site Status

Greenfield Park, Quebec, Canada

Site Status

Lachine, Quebec, Canada

Site Status

Longueuil, Quebec, Canada

Site Status

Longueuil, Quebec, Canada

Site Status

Mirabel, Quebec, Canada

Site Status

Montreal, Quebec, Canada

Site Status

Montreal, Quebec, Canada

Site Status

Montreal, Quebec, Canada

Site Status

Montreal, Quebec, Canada

Site Status

Québec, Quebec, Canada

Site Status

Québec, Quebec, Canada

Site Status

Saint-Lambert, Quebec, Canada

Site Status

Trois-Rivières, Quebec, Canada

Site Status

Val-d'Or, Quebec, Canada

Site Status

Beijing, , China

Site Status

Nanchang, , China

Site Status

Shijiazhuang, , China

Site Status

Benátky nad Jizerou, , Czechia

Site Status

Jindřichův Hradec, , Czechia

Site Status

Ostrava, , Czechia

Site Status

Pardubice, , Czechia

Site Status

Prague, , Czechia

Site Status

Slaný, , Czechia

Site Status

Trutnov, , Czechia

Site Status

Århus N, , Denmark

Site Status

Ballerup Municipality, , Denmark

Site Status

Hvidovre, , Denmark

Site Status

Vejle, , Denmark

Site Status

Pessac, , France

Site Status

Budapest, , Hungary

Site Status

Budapest, , Hungary

Site Status

Debrecen, , Hungary

Site Status

Kisvárda, , Hungary

Site Status

Komárom, , Hungary

Site Status

Nagykanizsa, , Hungary

Site Status

Pécs, , Hungary

Site Status

Úrhida, , Hungary

Site Status

Aguascalientes, , Mexico

Site Status

Aguascaliente, , Mexico

Site Status

Celaya, , Mexico

Site Status

Chihuahua City, , Mexico

Site Status

Cuernavaca, , Mexico

Site Status

D. F., , Mexico

Site Status

Durango, , Mexico

Site Status

Guadalajara, , Mexico

Site Status

Guadalajara, , Mexico

Site Status

Guadalajara, , Mexico

Site Status

Mexico City, , Mexico

Site Status

Monterrey, , Mexico

Site Status

Monterrey, , Mexico

Site Status

Pachuca, , Mexico

Site Status

Querétaro, , Mexico

Site Status

San Luis Potosi S.l.p., , Mexico

Site Status

San Luis Potosí City, , Mexico

Site Status

San Luís Potosí, , Mexico

Site Status

Tampico, , Mexico

Site Status

Alkmaar, , Netherlands

Site Status

Amsterdam, , Netherlands

Site Status

Apeldoorn, , Netherlands

Site Status

Breda, , Netherlands

Site Status

Delft, , Netherlands

Site Status

Eindhoven, , Netherlands

Site Status

Eindhoven, , Netherlands

Site Status

Gouda, , Netherlands

Site Status

Groningen, , Netherlands

Site Status

Heerlen, , Netherlands

Site Status

Hoorn, , Netherlands

Site Status

Leiden, , Netherlands

Site Status

Rotterdam, , Netherlands

Site Status

Rotterdam, , Netherlands

Site Status

Utrecht, , Netherlands

Site Status

Velp, , Netherlands

Site Status

Venlo, , Netherlands

Site Status

Zoetermeer, , Netherlands

Site Status

Bialystok, , Poland

Site Status

Gdansk, , Poland

Site Status

Gdynia, , Poland

Site Status

Katowice, , Poland

Site Status

Krakow, , Poland

Site Status

Lodz, , Poland

Site Status

Lodz, , Poland

Site Status

Lublin, , Poland

Site Status

Lublin, , Poland

Site Status

Lublin, , Poland

Site Status

Poznan, , Poland

Site Status

Pulway, , Poland

Site Status

Ruda Śląska, , Poland

Site Status

Warsaw, , Poland

Site Status

Warsaw, , Poland

Site Status

Almería, Almeria, Spain

Site Status

Barcelona, Barcelona, Spain

Site Status

Madrid, Madrid, Spain

Site Status

Madrid, Madrid, Spain

Site Status

Málaga, Malaga, Spain

Site Status

Birmingham, , United Kingdom

Site Status

Cardiff, , United Kingdom

Site Status

Glasgow, , United Kingdom

Site Status

Liverpool, , United Kingdom

Site Status

Manchester, , United Kingdom

Site Status

Reading, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil Bulgaria Germany India Israel Russia Taiwan Ukraine United States Australia Canada China Czechia Denmark France Hungary Mexico Netherlands Poland Spain United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-001891-21

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

NC25608

Identifier Type: -

Identifier Source: org_study_id